EUCTR2016-003736-21-GB进行中（未招募）1 期
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Diagnosis of relapsed/refractory DLBCL as documented by medical records and with histology based on criteria established by WHO:
- •a. If a subject has de novo DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically characterized as de novo non-GCB DLBCL or de novo GCB DLBCL. Note that PMBCL is excluded from this protocol. Tumor tissue must also be available for sending to the sponsor for central cell of origin testing.
- •b. If the subjects has RS, the diagnosis is confirmed by biopsy and is immunohistologically characterized as
- •transformation to DLBCL. Tumor tissue must also be available for sending to the sponsor for central pathology
- •testing. This histology applies to Part 1 only.
- •c. If the subjects has transformed DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically
- •characterized as transformation to DLBCL from indolent lymphoma (eg, follicular lymphoma). Tumor tissue must also be available for sending to the sponsor for central pathology testing. This histology applies to Part 1 only.
- •2. Men and women =18 years of age.
- •3. Prior treatment for lymphoid malignancy:
- •a. If the subject has DLBCL, there is no curative option with conventional therapy and the prior treatment included = 1 prior combination chemoimmunotherapy regimen (eg, anthracycline based therapy with rituximab such R-CHOP). Also subjects should have relapsed after ASCT or should be noncandidates for ASCT.
- •b. If the subject has RS, the subject must have had =1 prior treatment with a combination chemoimmunotherapy regimen.
- •4. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a =1.5 cm lesion, as measured in the longest dimension by CT scan for all histologies).
- •5. Documented active disease that is relapsed or refractory defined as:
- •a. Relapse: disease progression after completion of the treatment regimen preceding entry into the study.
- •b. Refractory: progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at =12 months from autologous stem cell
- •transplantation (Crump et al 2017).
- •6. ECOG performance status of =2.
- •7. Adequate hematologic function, independent of transfusion and growth factor support for =14 days before
- •screening, defined as:
- •a. ANC >1000 cells/mm3 (1.0 x 109/L)
- •b. Platelet count >75,000 cells/mm3 (75 x 109/L) or >50,000 cells/mm3 with bone marrow involvement
- •c. Hemoglobin >8.0 g/dL
- •8. Adequate hepatic and renal function at screening defined as:
- •a. Serum AST and ALT =2.5 x ULN if no demonstrable liver involvement or =3 x ULN in the presence of liver
- •b. Bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
- •c. Serum creatinine =1.5 times ULN and creatinine clearance >30 mL/min (measured or calculated by Cockcroft and Gault equation [(140-Age) • Mass (kg)/(72 • creatinine mg/dL) • multiply by 0.85 if female])
- •9. PT/INR <1.5 x ULN and aPTT <1.5 x ULN.
排除标准
- •1. History of prior malignancy except for the following:
- •a) Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician.
- •b) Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer.
- •c) Adequately treated carcinoma in situ without current evidence of disease.
- •2. As judged by the Investigator, any evidence of severe or uncontrolled systemic disease, or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses or uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study drug.
- •3. Diagnosis of PMBCL.
- •4. Known history of infection with HIV.
- •5. Serologic status reflecting active hepatitis B or C infection.
- •6. Active CMV infection
- •7. Undergone any of the following procedures or experienced any of the following conditions currently or in the preceding 6 months:
- •a) coronary artery bypass graft
- •b) angioplasty
- •c) vascular stent
- •d) myocardial infarction
- •e) angina pectoris
- •f) congestive heart failure (NYHA Grade =2)
- •g) ventricular arrhythmias requiring continuous therapy
- •h) supraventricular arrhythmias, including atrial fibrillation, which are uncontrolled
- •i) hemorrhagic or thrombotic stroke, including transient ischemic attacks or any other central nervous system
- •8. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting GI function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
- •9. History of CNS lymphoma, leptomeningeal disease or spinal cord compression.
- •10. History of severe allergic or anaphylactic reactions to kinase inhibitors or history of hypersensitivity to active or inactive excipients of vistusertib or acalabrutinib or drugs with a similar chemical structure or class to vistusertib or acalabrutinib.
- •11. Presence of a GI ulcer diagnosed by endoscopy within 3 months before screening.
- •12. Uncontrolled Type 1 or Type 2 diabetes mellitus.
- •13. Any clinically significant pre-existing renal disease or high risk of developing renal impairment.
- •14. Major surgical procedure within 28 days before first dose of study drug. .
- •15. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to CTCAE, Version 4.03 Grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria, with the exception of alopecia.
- •16. Any hematopoietic growth factors within 7 days of the first dose of study drug or pegylated G-CSF (pegfilgrastim) or darbepoetin within 14 days of the first dose of study drug.
- •17. Vaccinated with live, attenuated
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of combination chemotherapy of panobinostat and decitabine, given after donor stem cell transplantation in patients with (very) poor risk AM(very) poor risk AML or RAEB with IPSS = 1.5MedDRA version: 18.0Level: LLTClassification code 10024329Term: LeukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003344-74-BEHOVON Foundation100
进行中（未招募）
1 期
A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation .EUCTR2017-002335-42-NLHOVON Foundation40
进行中（未招募）
1 期
This study is being done to test the safety and efficacy of an investigational drug called AZD6738, when taken alone and when taken in combination with another investigational drug called acalabrutinib (also known as ACP-196).EUCTR2016-003737-15-GBAcerta Pharma BV50
进行中（未招募）
1 期
This study is being done to test the safety and efficacy of an investigational drug called AZD6738, when taken alone and when taken in combination with another investigational drug called acalabrutinib (also known as ACP-196).Relapsed or Refractory High-risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864EUCTR2016-003737-15-PLAcerta Pharma BV50
进行中（未招募）
1 期
This study will use a new investigation study drug called OMS906 in peoplewith C3 Glomerulopathy (C3G) or Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN). The purpose of this study is to test the safety and describe the effect of OMS906 study drug in people with these diseases.C3 Glomerulopathy and Idiopathic Immune Complex-Mediated GlomerulonephritisMedDRA version: 21.1Level: LLTClassification code: 10064758Term: Immune complex glomerulonephritis Class: 10038359CTIS2023-508669-33-00Omeros Corp.20